Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MLYS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMineralys Therapeutics reports Q4 and full-year 2025 financial results
Filed March 12, 2026 · Period ending March 12, 2026 · ~1 min read
Key Changes
-
medium
Company announced fourth quarter and full fiscal year 2025 financial results along with a corporate update via press release on March 12, 2026.
Item 2.02 verify on EDGAR → -
low
The 8-K filing references the press release but does not include actual financial figures or performance metrics in the filing body itself.
8-K body view on EDGAR → -
low
Information is furnished under Item 2.02, meaning it is not formally 'filed' and carries limited legal liability compared to standard SEC filings.
Item 2.02 disclaimer verify on EDGAR →
Summary
Mineralys Therapeutics issued its fourth quarter and full-year 2025 financial results on March 12, 2026, through a press release attached to this 8-K filing. This is a routine quarterly earnings disclosure that biotech companies make to update investors on financial performance and operational progress. The filing itself is procedural, using the standard Item 2.02 format where results are 'furnished' rather than formally 'filed,' which is typical for earnings announcements.
For retail investors, the key information would be in the attached press release (Exhibit 99.1), which is not detailed in this filing summary. Investors should review the actual press release to understand the company's cash position, burn rate, clinical trial progress, and any forward guidance. As a clinical-stage biotech, watch for updates on drug development milestones and runway—how long current cash will fund operations before additional financing is needed.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On March 12, 2026, Mineralys Therapeutics, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2025 and provided a corporate update.
The company disclosed its fourth quarter and full fiscal year 2025 financial results through a press release. The 8-K itself does not contain the actual financial figures or corporate update details, only references the attached press release (Exhibit 99.1).
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act
This is standard boilerplate language for earnings announcements furnished under Item 2.02. It means the information is disclosed but not formally "filed," limiting legal liability and preventing automatic incorporation into other SEC filings unless specifically referenced.
Event · Item 9.01 — Financial Statements and Exhibits
Mineralys Therapeutics filed an 8-K attaching a press release issued March 12, 2026; no material business event disclosed in filing body.
Added in current filing · view on EDGAR →
99.1
Press Release Issued on March 12, 2026
The company attached a press release dated March 12, 2026 as Exhibit 99.1. The 8-K body does not describe the press release content, so the nature of the disclosure cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify